Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19 - Sociedad Española de Trombosis y Hemostasia
Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients - eClinicalMedicine
Xarelto: Investigational Agent for Treatment and Prevention of Thromboembolic Events - Clinical Trials Arena
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial - The Lancet
Xarelto - Kardioközpont
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial - The Lancet
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week | Journal of the American College of Cardiology
Abstract 10011: Oral Rivaroxaban versus Subcutaneous Enoxaparin in the Prophylaxis of Covid-19 Induced Coagulopathy in Mild to Moderate Sars Cov-2 Infection | Circulation
Blood thinner Xarelto now has 11 indications; here's a look at the latest two - Drug Discovery and Development
X-এ Professor Beverley Hunt OBE 🇺🇦: "Rivaroxaban 20mg for hospitalised pts with COVID-19 does not improve outcome & increased bleeding when compared to “normal”thromboprophylaxis from this presentation. Looking forward to seeing the
Eliquis, Jardiance and Xarelto lead CMS list of drugs subject to negotiation | Healthcare Finance News
SciELO - Brasil - Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII) Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve
Rivaroxaban May Yet Protect After a Hospital Stay: MARINER | tctmd.com
VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19 | 2 Minute Medicine
ACTION: Rivaroxaban-based anticoagulation strategy fails to improve outcomes in COVID-19
Information about the new oral anticoagulant Xarelto® | Vinmec
Therapeutic Rivaroxaban: Risk Outweighs Benefit in Stable COVID
Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trial - eClinicalMedicine
Xarelto - Trombózis- és Hematológiai Központ
Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL | tctmd.com
Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19 - Sociedad Española de Trombosis y Hemostasia
RACGP - What GPs need to know about the new COVID antivirals
XARELTO 15 mg filmtabletta | Házipatika
